AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05032976 — intervention group
Intervention type: BIOLOGICAL
Intervention: Famtozinameran 5 to 11 Years of age
Description: The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age (orange cap) is administered after dilution by intramuscular injection (IM) of 0.2mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19.
Study NCT05032976 — intervention group
Intervention type: BIOLOGICAL
Intervention: Raxtozinameran 12 years of age and older
Description: BNT162b2 OMI XBB.1.5 (grey cap) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.~For individuals who have previously been vaccinated with a COVID-19 vaccine, BNT162b2 OMI XBB.1.5 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine.
Study NCT05032976 — intervention group
Intervention type: BIOLOGICAL
Intervention: Raxtozinameran 6 months to 4 years of age
Description: BNT162b2 OMI XBB.1.5 (maroon cap) is administered intramuscularly after dilution. For infants and children 6 months to 4 years of age without history of completion of a COVID-19, each 0.2 mL of dose is administered for a total of three vaccinations. The second dose is administered 3 weeks after the first dose followed by a third dose administered at least 8 weeks after the second dose. For infants and children 6 months to 4 years of age with history of completion of a COVID-19 primary course or prior SARS CoV-2 infection, a single dose of 0.2 mL is administered.
Study NCT04996576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infrazygomatic approach sphinopalatine ganglion block
Description: A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected
Study NCT04996576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intranasal injection approach of sphinopalatine ganglion block
Description: method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia
Study NCT05069363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-Body Photobiomodulation Therapy
Description: * All participants entering the trial will receive a course of whole-body PBM therapy~* The NovoTHOR Whole-Body PBM therapy device consists of a hinged, clamshell design with light-emitting diodes (LEDs) arranged to emit near-infrared and visible red light therapy is delivered to the entire body at once.~* Participants will be expected to lie horizontal in the device with the lid as closed as they are comfortable with.~* 18 sessions is the currently recommended and widely instituted and accepted practice with the NovoTHOR device.~* The LED equipment delivers red and near infrared light therapy to the participant~* Session 1 = 6 minutes~* Session 2 = 12 minutes~* Sessions 3-18 = 20 minutes~* Timescale: 3 treatments/week for 6 weeks~* The dosage of LED light (also known as 'fluence') will be equivalent to 25J/cm2. The device will supply a dual wavelength of red and near-infrared light with a 50:50 ratio; 660nm and 850nm respectively
Study NCT05271708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fespixon cream
Description: Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
Study NCT05271708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
Study NCT05647382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood cell analysis, blood gas surveillance, chest radiograph and echocardiography
Description: Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
Study NCT05647382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: blood cell analysis, blood gas surveillance, chest radiograph and echocardiography
Description: Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
Study NCT05462548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept Injectable Product
Description: 1-1.25mg/kg every 3 weeks subcutaneous injection
Study NCT05205239 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoluminal image analysis by capsule endoscopy
Description: Studies will be performed after discontinuation of medications that could affect gastrointestinal motility for at least 48 hours and overnight fast. Endoluminal images were obtained with the Pillcam capsule (Pillcam SB3 video capsule; Medtronic). Images will be obtained at a fixed 2 per second rate and recorded for a total of 8 hours with the subjects lying comfortably on a hospital bed and the trunk raised 30° above horizontal. Forty-five minutes after gastric exit, participants will be instructed to ingest a liquid meal (Ensure HN; Abbott; 300 mL,1 Kcal/mL). Endoluminal images of the small bowel will be analyzed with a computer program specifically developed in our laboratory for the evaluation of intestinal motility. This previously validated program is based on computer vision techniques, which allow the detection and quantification of contractile and non-contractile patterns characterizing small bowel motility.
Study NCT05101291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: Interventional anaesthesia provided through an indwelling spinal catheter was administered according to protocol
Study NCT05652660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471
Description: Experimental
Study NCT05652660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Probe substrate
Study NCT04770155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Nitrates 400 mg
Description: The nitrates in the beetroot juice will be absorbed and reduced in the plasma to nitrite and nitric oxide, increasing endothelium-independent nitric oxide bioavailability.
Study NCT04770155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Nitrates 400 mg
Description: The nitrates in the beetroot juice will be absorbed and reduced in the plasma to nitrite and nitric oxide, increasing endothelium-independent nitric oxide bioavailability.
Study NCT04770155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline 3 g
Description: Ingested L-citrulline becomes available in large quantities in the plasma for enzymatic conversion into L-arginine. The activity of the endothelial nitric oxide synthase converts L-arginine into nitric oxide, increasing endothelium-dependent nitric oxide bioavailability.
Study NCT04770155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-citrulline 3 g
Description: Ingested L-citrulline becomes available in large quantities in the plasma for enzymatic conversion into L-arginine. The activity of the endothelial nitric oxide synthase converts L-arginine into nitric oxide, increasing endothelium-dependent nitric oxide bioavailability.
Study NCT04770155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil 100 mg
Description: Sildenafil inhibits phosphodiesterase 5, an enzyme that degrades cyclic guanosine monophosphate in the vascular smooth muscle cells inactivating the nitric oxide-mediated signal; thus, Sildenafil will prolong the availability of cyclic guanosine monophosphate, enhancing the nitric oxide-mediated intracellular cascade.
Study NCT04770155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil 100 mg
Description: Sildenafil inhibits phosphodiesterase 5, an enzyme that degrades cyclic guanosine monophosphate in the vascular smooth muscle cells inactivating the nitric oxide-mediated signal; thus, Sildenafil will prolong the availability of cyclic guanosine monophosphate, enhancing the nitric oxide-mediated intracellular cascade.
Study NCT04770155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan 125 mg
Description: Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.
Study NCT04770155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bosentan 125 mg
Description: Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.
Study NCT04859803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients will be received rhomboid intercostal block under ultrasound guidance.
Description: Following endotracheal intubation, patients allotted to the RIB group were positioned in the lateral decubitus position with the chest on the operating side lying superiorly. The ipsilateral arm was abducted from the chest to move the scapula laterally. The RIB was performed as described previously \[8\]. A high-frequency (6-12 MHz) linear ultrasound probe (LOGIQ e ultrasonic system, Deutschland GmbH \& Co. KG, Solingen, Germany) was placed medial to the medial border of the scapula in the oblique sagittal plane. The landmarks, i.e., the trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung, were identified in the ultrasound. Under aseptic conditions, an 80-mm 21-gauge needle was inserted at the level of T6-7 in the ultrasound view. A single dose of 30 ml 0.25% bupivacaine will be injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography.
Study NCT04859803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional intravenous analgesia
Description: Following endotracheal intubation, patients will be received morphine sulfate (0.02 mg/kg) bolus doses were used to preserve MAP and HR within 20% of pre-induction readings
Study NCT06272929 — intervention group
Intervention type: DEVICE
Intervention: doppler ultrasound
Description: doppler US
Study NCT06450340 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate-intensity aerobic exercise refers to rhythmic and long-lasting exercise with increased heart rate, slight sweating and slight wheezing.
Description: Sessions lasted 60 minutes each and took place three times a week for 12 weeks for each of the study groups.
Study NCT06450340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise refers to rhythmic and long-lasting exercise with increased heart rate, slight sweating and slight wheezing.
Description: Sessions lasted 60 minutes each and took place three times a week for 12 weeks for each of the study groups.
Study NCT04973293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: Sintilimab 200 mg, 4 cycles of treatment before surgery
Study NCT04973293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab 15 mg/kg, 4 cycles of treatment before surgery
Study NCT04924452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser conditioning and Sealant application
Description: Sealant application protocol includes: a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar; tooth surface will be washed for debris and organic residue removal and dried with air spray; isolation; laser conditioning of the occlusal enamel surface. The parameter settings used will be: tip-to-tissue distance 1.5mm from the tooth surface; tip diameter 600 µm; laser energy 70 mJ; pulse frequency 10 Hz; water spray level 8; average power 0.7 W; energy density 67 J/cm2; tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time; reisolation; tooth surface will be dried with air spray for 15s; fissure sealant application (Pit\&Fissure Sealant, DMP Ltd); light cured for 20 seconds.
Study NCT04924452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sealant application
Description: Sealant application protocol includes: a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar; tooth surface will be washed for debris and organic residue removal and dried with air spray; isolation; tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time; reisolation; tooth surface will be dried with air spray for 15s; fissure sealant application (Pit\&Fissure Sealant, DMP Ltd); light cured for 20 seconds.
Study NCT05504330 — intervention group
Intervention type: DRUG
Intervention: Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin
Description: First of all, ICAS patients were given health education to exhort them to reduce the risk factors of exposure to stroke and get rid of their unhealthy lifestyles. Secondly, for patients in need, standardize their dosage and course of treatment, mainly including antiplatelet drugs and statins. In addition, patients with diabetes and hypertension urge rational medication to control blood pressure and blood glucose level.
Study NCT05533554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention Based on the Theory of Planned Behavior to Reduce Alcohol Consumption in University Students
Description: Cognitive-behavioral intervention where the key concepts of the Theory of Planned Behavior were operationalized from which two intervention sessions were formed and the most appropriate techniques were chosen to influence the key concepts of the theory: behavioral beliefs, subjective norms, perceived behavioral control and self-efficacy. The program is made up of 3 evaluation sessions (pre and post a month later) and 2 intervention sessions with a duration of 120 minutes each.
Study NCT05167786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive spinal stimulation with gait training
Description: Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform lower limb locomotor activities.
Study NCT05167786 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive spinal stimulation
Description: Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation to subjects.
Study NCT05167786 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional gait training
Description: Subjects will receive lower limb locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
Study NCT05167786 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Subject will not receive either transcutaneous electrical spinal cord stimulation or perform lower limb locomotor activities.
Study NCT05167786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exploratory Phase - Optimization of Gait Training and Spinal Stimulation
Description: Subjects may receive various lower limb locomotion training with or without transcutaneous spinal cord stimulation. Training approaches may include but are not limited to single or split belt treadmill and over ground walking. Transcutaneous Spinal Cord Neurostimulator may deliver a variety of transcutaneous electrical spinal cord stimulation to subjects.
Study NCT05167786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exploratory Phase - Optimization of Gait Training and Spinal Stimulation
Description: Subjects may receive various lower limb locomotion training with or without transcutaneous spinal cord stimulation. Training approaches may include but are not limited to single or split belt treadmill and over ground walking. Transcutaneous Spinal Cord Neurostimulator may deliver a variety of transcutaneous electrical spinal cord stimulation to subjects.
Study NCT05167786 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exploratory Phase - Optimization of Gait Training and Spinal Stimulation
Description: Subjects may receive various lower limb locomotion training with or without transcutaneous spinal cord stimulation. Training approaches may include but are not limited to single or split belt treadmill and over ground walking. Transcutaneous Spinal Cord Neurostimulator may deliver a variety of transcutaneous electrical spinal cord stimulation to subjects.
Study NCT04924452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser therapy
Description: Er:YAG laser (LiteTouch, Light Instruments LTD), emission wavelength 2940 nm will be used for caries removal - parameters: enamel removal - energy 100-200mJ; density 9.84-13.03 J/cm2, pulse frequency 20Hz; tip diameter 800 μm; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface; dentin removal - energy 100mJ; density 9.84 J/cm2, pulse frequency 20Hz; tip diameter 800 μm; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface. Restoration with compomer.
Study NCT04924452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional rotary instruments will be used for caries removal - high-speed and low-speed dental handpieces. Restoration with compomer.
Study NCT05495399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spondylectomy
Description: Patient will be randomized to treated by spondylectomy or debulking surgery. Spondylectomy implied total resection of involved spine; while debulking surgery means partial resection of involved spine.
Study NCT05495399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spondylectomy
Description: Patient will be randomized to treated by spondylectomy or debulking surgery. Spondylectomy implied total resection of involved spine; while debulking surgery means partial resection of involved spine.
Study NCT05495399 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Patient received debulking surgery will be randomized to receive SBRT or conventional RT. SBRT means high dose per fraction compared to conventional RT.
Study NCT05442775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv
Description: Oral tablet
Study NCT05427955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-level Erector Spinae Plane Block
Description: One-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 30 ml of 0.25% bupivacaine will be injected at the T5 level.
Study NCT05427955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bi-level Erector Spinae Plane Block
Description: Bi-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 15 ml of 0.25% bupivacaine at T4 level and 15 ml of 0.25% bupivacaine at T6 level will be injected.
Study NCT05461807 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
Study NCT05461807 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
Study NCT04780438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Patients rendomized in this arm will receive dapagliflozin at a target dose of 10mg once daily.
Study NCT05409612 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Supemtek®
Description: Quadrivalent recombinant high-dose influenza vaccine containing 45 µg of hemagglutinin (HA) for each of the 4 strains included (2 strains A and 2 strains B).~Solution for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.
Study NCT05409612 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigriptetra®
Description: Quadrivalent inactivated influenza vaccine containing 15 µg of hemagglutinin (HA) for each of the 4 strains included. Suspension for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.
Study NCT04780438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients rendomized in this arm will receive placebo.
Study NCT06198660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: positional release technique
Description: positional release techniques in addition to conventional therapy two sessions per week for 6 weeks
Study NCT06198660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positional release technique
Description: positional release techniques in addition to conventional therapy two sessions per week for 6 weeks